Search

for
Search:

Research

5 / 1000+ results

research Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients

2 citations , October 2025 in “Frontiers in Medicine”

This study found that deuruxolitinib may effectively improve hair regrowth and patient satisfaction in moderate to severe alopecia areata, but careful monitoring is needed due to manageable side effects and concerns about long-term safety.

research Table 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx

October 2025 in “Figshare”

This meta-analysis found that deuruxolitinib significantly improved hair regrowth and patient satisfaction in those with moderate to severe alopecia areata compared to placebo, though it was associated with manageable side effects such as elevated creatinine kinase levels, headaches, and acne, especially at higher doses.

research Supplementary file 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx

October 2025 in “Figshare”

This systematic review and meta-analysis reported that deuruxolitinib is effective for hair regrowth and improving patient-reported outcomes in individuals with moderate to severe alopecia areata, but observed manageable treatment-emergent adverse events such as elevated creatinine kinase levels and headaches, particularly with higher doses.

research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials

25 citations , November 2022 in “British journal of dermatology/British journal of dermatology, Supplement”

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

Ixekizumab Shows Efficacy and Safety in Patients Who Failed Biweekly Etanercept Therapy: Analysis From UNCOVER-2, a Phase 3 Randomized Clinical Trial in Psoriasis

research Ixekizumab shows efficacy and safety in patients who failed biweekly etanercept therapy: Analysis From UNCOVER-2, a phase 3 randomized clinical trial in psoriasis

April 2016 in “Journal of The American Academy of Dermatology”

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

View more "treatment-emergent adverse event" in research →

Community Join

1 / 1000+ results

community What’s your views on clascoterone 5% topical solution by cosmo

23 upvotes 9 months ago

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

View more "treatment-emergent adverse event" in community →

Clinics

1 / 14 results

59
TrichologyHair Loss Treatments
Glam 4 EventsRoseville, CA · US

Learn

— no results

Try a deeper search in learn →

Experts

— no results

Try a deeper search in experts →